Welcome to our dedicated page for Cardinal Health news (Ticker: CAH), a resource for investors and traders seeking the latest updates and insights on Cardinal Health stock.
Cardinal Health, Inc. (NYSE: CAH) is a global leader in integrated healthcare services and products. With nearly 100 years of experience, the company stands as a pillar in the healthcare industry, ranking among the top 25 on the Fortune 500 list. Cardinal Health offers a comprehensive suite of services that cater to hospital systems, pharmacies, ambulatory surgery centers, clinical laboratories, and physician offices worldwide.
Operating through two main segments—Pharmaceuticals and Medical—Cardinal Health provides clinically-proven medical products and pharmaceuticals, alongside cost-effective solutions that enhance supply chain efficiency. The company is a major distributor of branded, generic, and specialty pharmaceutical products to a wide array of clients, including retail chains, independent pharmacies, hospital networks, and healthcare providers.
Recently, Cardinal Health reported strong financial results for Q2 FY2024, with a 12% increase in revenue to $57.4 billion. The company also saw significant growth in both its Pharmaceutical and Medical segments, driven by robust sales of brand and specialty pharmaceuticals, as well as improvements in at-Home Solutions and Global Medical Products and Distribution. CEO Jason Hollar highlighted the company's operational execution and strategic priorities, which include tech-enabled specialty acquisitions and a focus on supply chain resiliency.
Cardinal Health is also committed to sustainability and corporate responsibility. The company recently released its Fiscal 2023 Environmental, Social and Governance (ESG) Report, emphasizing long-term value creation through sustainable practices. The company has received approval from the Science Based Targets initiative (SBTi) for its ambitious greenhouse gas (GHG) emissions reduction targets. By FY2023, Cardinal Health had already reduced its Scope 1 and 2 emissions by 13% from a FY2019 base year.
In terms of infrastructure, Cardinal Health is expanding its logistics capabilities. The company has commenced construction on a new 350,000 square-foot Consumer Health Logistics Center in Columbus, Ohio, designed to support the distribution of over-the-counter consumer health products. This facility, expected to be operational by Summer 2025, will create approximately 100 new jobs and enhance Cardinal Health's supply chain agility.
Despite challenges such as the non-renewal of its pharmaceutical distribution contracts with OptumRx, Cardinal Health remains resilient. The company reaffirmed its fiscal 2024 non-GAAP diluted EPS guidance and is confident in its long-term growth targets.
For more information, visit cardinalhealth.com and follow @cardinalhealth on Twitter.
Cardinal Health (NYSE: CAH) announced the construction of a new 340,000 square foot distribution center in Fort Worth, Texas, supporting its at-Home Solutions business. The facility will consolidate two existing warehouses, adding 74,000 square feet of inventory capacity while retaining current workforce. The center will ship approximately 10,000 packages daily to patients nationwide.
The facility will feature advanced technology including 74 robots, a 1,500-foot automated conveyor system, and four automated box-making machines producing 500 custom boxes hourly. It will utilize a cloud-based warehouse management system with AI capabilities for inventory management. The company reported its best-ever metrics in quality, service, efficiency, and employee safety in Q1 FY2025. The facility is expected to be fully operational by Summer 2025.
Cardinal Health (NYSE: CAH) has announced it will release its second-quarter financial results for fiscal year 2025 on January 30, before the New York Stock Exchange opens. The company will host a webcast discussion of the results starting at 8:30 a.m. Eastern. Investors can access the webcast and accompanying slide presentation through Cardinal Health's Investor Relations page without requiring an access code. The presentation materials and webcast replay will remain available on the company's Investor Relations page for 12 months.
Cardinal Health (NYSE: CAH) announced the U.S. launch of its Kendall SCD SmartFlow™ Compression System, an advanced solution for preventing deep vein thrombosis and pulmonary embolism. The system features Vascular Refill Detection technology that customizes compression cycles to match patient's unique vascular refill time, increasing blood flow efficiency. Notable features include Patient Sensing™ Technology that automatically detects therapy application and alerts for incorrect usage. The system will be available internationally in early 2025.
Cardinal Health (NYSE: CAH) has entered into a definitive agreement to acquire Advanced Diabetes Supply Group (ADSG), a national distributor of diabetes-related Durable Medical Equipment. ADSG, headquartered in Carlsbad, CA, serves approximately 500,000 patients through home delivery of diabetes products, including continuous glucose monitoring devices and testing supplies. The company will join Cardinal Health's at-Home Solutions business, which currently serves over 5 million patients annually. The acquisition is pending customary closing conditions and regulatory approvals.
Cardinal Health (NYSE: CAH) announced two strategic acquisitions: a 71% stake in GI Alliance (GIA) for $2.8 billion and Advanced Diabetes Supply Group (ADSG) for $1.1 billion. GIA, the leading gastroenterology management services organization with over 900 physicians across 345 locations, will operate within Cardinal's Pharmaceutical and Specialty Solutions segment. ADSG, serving approximately 500,000 diabetes patients annually, will merge with Cardinal's at-Home Solutions business. Both acquisitions are expected to close in early 2025 and be accretive to revenue, segment profit growth, and non-GAAP EPS in the first 12 months post-closing.
Cardinal Health (NYSE: CAH) has announced that its Board of Directors has approved a quarterly dividend of $0.5056 per share from the company's capital surplus. The dividend will be paid on January 15, 2025, to shareholders who are on record as of January 2, 2025.
Cardinal Health (CAH) reported Q1 FY2025 results with revenue decreasing 4% to $52.3 billion, though showing 15% growth excluding a large customer contract expiration. Non-GAAP operating earnings increased 12% to $625 million, driven by Pharmaceutical and Specialty Solutions segment growth. Non-GAAP diluted EPS rose 9% to $1.88. The company raised its FY2025 non-GAAP EPS guidance to $7.75-$7.90. Notable developments include a $1.1B agreement to acquire Integrated Oncology Network and completion of a $375M accelerated share repurchase program.
Cardinal Health (NYSE: CAH) has opened a new distribution center in Boylston, Massachusetts, replacing its Bedford facility with nearly 317,000 square feet of space. The new center doubles warehouse space and triples product storage capacity, serving healthcare customers across New England. Opening in early 2025, it features specialized handling capabilities including refrigeration and hazardous materials storage.
The facility enhances supply chain resiliency and operational efficiency for the region's healthcare providers. This expansion follows Cardinal Health's recent openings of a 310,000-square-foot replenishment center in Montgomery, New York (2023), and announcements of new distribution centers in Walton Hills, Ohio, and Greenville, South Carolina.
Cardinal Health (NYSE: CAH) has announced that it will release its first-quarter financial results for fiscal year 2025 on November 1, before the New York Stock Exchange opens for trading. The company will host a webcast discussion of the results at 8:30 a.m. Eastern. Investors can access the webcast and accompanying slide presentation through Cardinal Health's Investor Relations page, with no access code required. The presentation slides and a replay of the webcast will remain available on the Investor Relations page for 12 months following the event.
Cardinal Health (NYSE: CAH) has announced a definitive agreement to acquire Integrated Oncology Network (ION) for $1.115 billion in cash. ION is a physician-led independent community oncology network with over 50 practice sites across 10 states, representing more than 100 providers. This acquisition aligns with Cardinal Health's strategy to invest in specialty and oncology services, particularly supporting independent community healthcare providers.
The transaction will integrate ION practices into Navista, Cardinal Health's oncology practice alliance. ION's comprehensive care services, including medical oncology, radiation oncology, and urology, will enhance Navista's advanced services and technology offerings. The acquisition is expected to be accretive to non-GAAP earnings per share after 12 months following the close, subject to customary closing conditions and regulatory approvals.
FAQ
What is the current stock price of Cardinal Health (CAH)?
What is the market cap of Cardinal Health (CAH)?
What services does Cardinal Health offer?
How did Cardinal Health perform in Q2 FY2024?
What is Cardinal Health's approach to sustainability?
What are Cardinal Health's main business segments?
What recent infrastructure developments has Cardinal Health announced?
How many employees does Cardinal Health have?
What are Cardinal Health's fiscal 2024 guidance and expectations?
How is Cardinal Health addressing supply chain efficiency?
What impact will the non-renewal of OptumRx contracts have on Cardinal Health?
Where can I find more information about Cardinal Health?
